End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.8 CNY | +0.20% | -1.92% | -37.05% |
04-26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
04-25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
ETFs positioned on Walvax Biotechnology Co., Ltd.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.09% | 2 M€ | -11.89% | - | |
0.54% | 2 M€ | -14.14% | ||
0.23% | 35 M€ | -5.85% | - | |
0.01% | 4 M€ | -4.41% | - | |
0.00% | 112 M€ | +4.91% | - | |
0.00% | 153 M€ | +7.16% | - | |
0.00% | 454 M€ | +8.71% | - | |
0.00% | 2,867 M€ | +9.66% | - | |
0.00% | 32 M€ | +8.03% | - | |
0.00% | 391 M€ | +8.36% | - | |
0.00% | 34 M€ | +8.28% | - | |
0.00% | 39 M€ | +5.65% | - | |
0.00% | 306 M€ | +5.71% | - | |
0.00% | 34 M€ | +3.53% | - | |
0.00% | 105 M€ | +3.32% | - | |
0.00% | 17 M€ | +2.84% | - | |
0.00% | 7 M€ | +5.65% | - | |
0.00% | 54 M€ | +0.39% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.05% | 3.27B | |
-1.57% | 89.37B | |
+2.76% | 40.65B | |
-12.32% | 32.81B | |
+52.41% | 25B | |
-17.39% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- 300142 Stock
- Funds and ETFs Walvax Biotechnology Co., Ltd.